	US 12,070,444 B2
	Modulation of molecular markers using S-equol
Rong Li, Washington, DC (US); Bin Yuan, Hefei (CN); and Kate Ida Lathrop, San Antonio, TX (US)
Assigned to Board of Regents, The University of Texas System, Austin, TX (US)
Filed by Board of Regents, The University of Texas System, Austin, TX (US)
Filed on Nov. 24, 2021, as Appl. No. 17/535,125.
Claims priority of provisional application 63/117,888, filed on Nov. 24, 2020.
Prior Publication US 2022/0160678 A1, May 26, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/353 (2006.01); A61K 39/00 (2006.01); A61K 39/395 (2006.01); A61P 35/00 (2006.01); C07K 16/28 (2006.01)

CPC A61K 31/353 (2013.01) [A61K 39/39541 (2013.01); A61P 35/00 (2018.01); C07K 16/2818 (2013.01); C07K 16/2827 (2013.01); A61K 2039/505 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01)]

16 Claims

1. A method of treating triple-negative breast cancer (TNBC) by

increasing tumor-infiltrating CD8+T cells, the method comprising:

administering to said patient a formulation comprising an amount of S-equol in combination with an antibody, wherein the antibody is directed to programmed cell death protein 1 (PD-1), wherein said combination is sufficient to increase tumor-infiltrating CD8+T cells and reduce the size of TNBC tumors.